In short
Research into Duchenne muscular dystrophy now spans steroid therapy, exon-skipping drugs, and gene therapy, with honest gaps still remaining.
On this page
01
What Duchenne Does to Muscle
Duchenne muscular dystrophy is a genetic condition, almost always affecting boys, caused by a lack of a protein called dystrophin that normally helps protect muscle fibers during use. Without it, muscle tissue is gradually damaged and replaced by scar and fat tissue, leading to progressive muscle weakness over childhood and adolescence.
The condition affects skeletal muscles used for movement as well as, over time, the heart and muscles involved in breathing, which is why care for Duchenne typically involves a coordinated team rather than a single specialist.
02
Steroids as the Current Standard
Corticosteroid medications have long been the standard supportive treatment, shown to help slow the loss of muscle strength and delay some disease milestones when started at an appropriate age and monitored carefully for side effects over years of use.
Steroids do not address the underlying genetic cause, but they remain a foundation of care for most people with Duchenne, often used alongside physical therapy and, more recently, alongside newer targeted therapies as those become appropriate for a given person's specific genetic mutation.
03
Exon Skipping and Gene Therapy Approaches
Exon-skipping therapies are designed to help cells skip over a faulty section of genetic code so a partially functional, shortened version of dystrophin can still be produced. These approaches are tailored to specific mutation types, meaning they apply to only a portion of people with Duchenne, not everyone.
Gene therapy approaches aim to deliver a modified, workable version of the dystrophin gene into muscle cells. Several such approaches have moved through clinical development, and ongoing research continues to study how much functional benefit they provide and over what time frame.
04
What Remains Uncertain
Newer therapies generally aim to slow progression or improve specific measures of muscle function rather than reverse existing damage, and researchers are still working out how durable these benefits are over many years, and for which patients they work best.
Anyone considering a newer therapy for Duchenne is encouraged to discuss the specific evidence, eligibility criteria, and monitoring requirements with a specialist familiar with the condition and with the person's particular genetic mutation.
Sources
- Duchenne and Becker Muscular Dystrophymedlineplus.gov
- Muscular Dystrophymedlineplus.gov
Share this story
Curious where your own values stand?
Two minutes from upload to a full visual picture. Free to analyze.